Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

This study is offering an immune cell therapy for transplant patients who develop serious viral infections — specifically cytomegalovirus (CMV) or adenovirus (AdV) — after a solid organ or bone marrow transplant. After transplants, patients must take immunosuppressive drugs to prevent rejection, which leaves them vulnerable to viral reactivation. This therapy uses virus-specific T-cells (cytotoxic lymphocytes, or CTLs) derived from a matched donor to help fight the infection. The CTLs are grown from a donor who has immunity to the specific virus, then infused into the patient. This approach targets the virus directly without the broad immune suppression that conventional antiviral drugs cause. You may be eligible if: - You are between 1 and 85 years of age - You have had a solid organ transplant or allogeneic stem cell transplant - You have documented CMV or adenovirus infection or reactivation that is not responding to antiviral treatment, or you cannot tolerate standard antiviral drugs - A suitable seropositive (immune) haploidentical or matched donor is available You may NOT be eligible if: - You have received T-cell depleting drugs (e.g., ATG, alemtuzumab) within the past 21 days - You are on high-dose steroids (> 0.5 mg/kg/day prednisone or equivalent) - You have a severe uncontrolled bacterial or fungal infection - You have active acute graft-versus-host disease (grades II-IV) requiring intensive immunosuppression - You have active, uncontrolled cancer relapse Talk to your doctor to see if this trial is right for you.